Patients and families are at the heart of every rare disease journey. Guided by their experiences, we are committed to transforming care in rare disease and advancing meaningful innovation where unmet needs remain.
Discover how advancing HER2 science is reshaping cancer care. By deepening understanding of tumor complexity and leveraging biomarker-driven approaches, we are enabling more precise therapies and driving innovation to improve outcomes for patients with HER2-expressing cancers and other areas of high unmet need. Each May, Brain Cancer Awareness Month highlights brain and other central nervous system cancers—some of the most complex and least understood. Despite recent advances, people with rare brain tumors still face delays in diagnosis, limited access to specialized care, and fewer treatment options when time matters most. People diagnosed with locally advanced/metastatic HER2-positive gastroesophageal adenocarcinoma continue to face limited treatment options with the need to improve outcomes. Discover why innovation in the first-line setting remains essential to improving care.